About Darryl

This author has not yet filled in any details.
So far Darryl has created 49 blog entries.

Androgen Deprivation Therapy (ADT) may not be the best way to fight advanced prostate cancer

Researchers from the University and the Sichuan Antibiotics Industrial Institute in China have discovered a novel treatment for advanced prostate cancer. For over forty years, ADT has been the foundation of advanced stage prostate cancer treatment. ADT is effective initially, most often measured by a drop in PSA measurement. But in almost all cases, prostate cancer returns and no longer uses androgen to fuel its growth.  This is called androgen-independent cancer or castration-resistant prostate cancer (CRPC). ADT does not have a significant effect on CRPC.  So, for now, CRPC is barely treatable. So, how are prostate cancer cells converted from androgen-dependent to [...]

By | March 15th, 2017|Advanced Prostate Cancer, Hormone Therapy|0 Comments

New Way to Do PET Scans

  There’s a better way to do a PET scan, by using radiotracer fluciclovine (fluorine-18; F-18) (Journal of Nuclear Medicine, March 2017) According to researcher Ashesh B. Jani, MD, Winship Cancer Institute of Emory University, Atlanta, Georgia, fluciclovine can improve imaging in recurrent prostate cancer patients with no additional radiation side effects. An improved PET scan helps patients and doctors see if their advanced stage targeted treatment is working.   For the study, 96 patients were enrolled in a clinical trial of radiotherapy for recurrent prostate cancer after prostatectomy. All patients underwent initial treatment planning based on results from conventional [...]

By | March 6th, 2017|Advanced Prostate Cancer, Imaging, NaF-PET/CT, Radiation|0 Comments

Relugolix – New Oral Hormone Treatment

There's a new Phase 3 clinical trial for an oral medication, taken one time per day, that will reduce testosterone for advanced prostate cancer. Myovant Sciences is testing their new drug, called Relugolix in a trial called, HERO. Relugolix lowers testosterone by inhibiting pituitary release of luteinizing hormone and follicle-stimulating hormone. Todays testosterone reducing therapies require injections and the most commonly used such as Lupron start off by raising testosterone and causing a clinical flare of symptoms. Relugolix decreases testosterone within days of initiation and might enable quick  testosterone recovery when treatment ends. That would be super for men thinking abou intermittent therapy. Seek out clinical [...]

By | March 2nd, 2017|Advanced Prostate Cancer, Hormone Therapy|0 Comments

USA Only-PSA Advocacy Opportunity-Include Your Voice

Here is a newly emerged advocacy opportunity regarding the PSA test and Prostate Cancer in the USA. Malecare feels you should be empowered to participate in this national health policy issue. CMS' Center for Medicare issued what is known as a Medicare Advantage Call letter. In the letter, the CMS signals to Medicare Advantage Plans that they will put a Healthcare Effectiveness Data and Information Set (HEDIS) "non-recommended PSA screening measure" as a display measure in 2018 and will consider it for the 2019 Star ratings. CMS is the US federal agency that administers Medicare, Medicaid, and the State Children's [...]

By | February 22nd, 2017|Advanced Prostate Cancer, Uncategorized|0 Comments